Rani Therapeutics Holdings, Inc.
RANI
$0.84
-$0.03-3.73%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 0.00% | 16.91% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.00% | 16.91% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 0.00% | 16.91% | |||
| SG&A Expenses | 12.96% | -3.95% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.87% | 0.51% | |||
| Operating Income | -5.86% | 2.30% | |||
| Income Before Tax | -5.07% | 11.67% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -5.07% | 11.67% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 4.89% | 179.77% | |||
| Net Income | -5.09% | 31.75% | |||
| EBIT | -5.86% | 2.30% | |||
| EBITDA | -6.09% | 2.05% | |||
| EPS Basic | -1.02% | 74.90% | |||
| Normalized Basic EPS | -0.89% | 77.35% | |||
| EPS Diluted | -1.02% | 74.90% | |||
| Normalized Diluted EPS | -0.89% | 77.35% | |||
| Average Basic Shares Outstanding | 3.98% | 172.15% | |||
| Average Diluted Shares Outstanding | 3.98% | 172.15% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||